1. Home
  2. News Archive

More News

Sustainability Movement Gains Traction, Impacts Growth in Reusable Instruments
Sustainability Movement Gains Traction, Impacts Growth in Reusable Instruments

In recent years, the world’s largest ophthalmic surgical societies have expressed increasing concern over the environmental impact of operating room waste generated annually by the world’s 50 milli...

2025-2026 Ophthalmic Meetings Calendar
2025-2026 Ophthalmic Meetings Calendar

Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.

Methotrexate Has ‘Avastin Moment’ at ASRS Meeting
Methotrexate Has ‘Avastin Moment’ at ASRS Meeting

Christopher Riemann, MD (US), was stunned when he initially saw the results from the first preplanned interim safety analysis of the Phase II FIXER trial on preventing proliferative vitreoretinopat...

ASRS Sessions Highlight Value of Amniotic Membrane in Retinal Surgery
ASRS Sessions Highlight Value of Amniotic Membrane in Retinal Surgery

The use of human amniotic membrane in vitreoretinal surgery was discussed in several sessions at the American Society of Retina Specialists’ 2025 meeting. Presentations suggest that this material w...

Speakers at ASRS Meeting Lament Dwindling Access to Operating Room
Speakers at ASRS Meeting Lament Dwindling Access to Operating Room

Access to the operating room (OR) was a hot topic at the 2025 meeting of the American Society of Retina Specialists. The majority of retina surgeons said access to the OR was an issue. Forty-nine p...

Cencora Steps into Major Role at ASRS Meeting Following Acquisition
Cencora Steps into Major Role at ASRS Meeting Following Acquisition

The 2025 ASRS scientific meeting was a first for Cencora as an operator of clinical trials, but not for its subsidiary Retina Consultants of America (RCA). Cencora (formerly AmerisourceBergen), bet...

Ocugen Leads Latest Ophthalmic Fundraising with $20 Million Offering
Ocugen Leads Latest Ophthalmic Fundraising with $20 Million Offering

Ocugen led recent ophthalmic fundraising efforts with a $20 million registered direct offering to advance its clinical gene therapy pipeline in retina. Financing announced in the past four weeks to...

Santen Launches Ryjunea Drops in Germany for Pediatric Myopia
Santen Launches Ryjunea Drops in Germany for Pediatric Myopia

Japan’s Santen Pharmaceutical announced July 22 that it had launched Ryjunea low-dose atropine eye drops in Germany for pediatric myopia. Germany is the first market for Ryjunea, which received EU ...

Boehringer Ingelheim and Re-Vana Sign Potential $1 Billion Collaboration Deal
Boehringer Ingelheim and Re-Vana Sign Potential $1 Billion Collaboration Deal

Boehringer Ingelheim and Re-Vana Therapeutics will collaborate to develop extended-release therapies for eye diseases in a deal worth potentially more than $1 billion for Re-Vana, the companies ann...

New Minnesota Law Expands ODs’ Authority for Drugs, Injections
New Minnesota Law Expands ODs’ Authority for Drugs, Injections

A new law passed in Minnesota expands optometrists’ authority to prescribe certain medications and allows them to administer some in-office injections. The Minnesota Optometric Association (MOA) ha...

Topcon Acquires Retinal Screening Platform to Improve Bidirectional Referrals
Topcon Acquires Retinal Screening Platform to Improve Bidirectional Referrals

Topcon Healthcare reported July 31 that it had acquired Intelligent Retinal Imaging Systems (IRIS), a Pensacola, Florida-based developer of cloud-based retinal screening technology. No financial de...

Clinical Trial Updates for Ophthalmic Candidates, August 2025
Clinical Trial Updates for Ophthalmic Candidates, August 2025

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Eye Physicians, Researchers Band Together to Stave Off NEI Cuts
Eye Physicians, Researchers Band Together to Stave Off NEI Cuts

The American Academy of Ophthalmology (AAO) announced July 23 that it had joined with other professional and vision research organizations to fight proposed funding cuts and consolidation threats a...

Emerging Companies Pursuing Ophthalmic Indications, August 2025
Emerging Companies Pursuing Ophthalmic Indications, August 2025

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Weekly Surgeon Poll, August 2025
Weekly Surgeon Poll, August 2025

August 2025 Ophthalmic News Briefs
August 2025 Ophthalmic News Briefs

Glaukos announced during its earnings call on July 30 that it had acquired Mobius Therapeutics, of St. Louis, Missouri, whose lead compound, Mitosol, is the only FDA approved ophthalmic formulation...

Myra Vision Gains IDE Approval to Begin US Trial of Adjustable Glaucoma Shunt
Myra Vision Gains IDE Approval to Begin US Trial of Adjustable Glaucoma Shunt

Myra Vision announced Aug. 12 that the US FDA had issued a conditional approval letter for its investigational device exemption (IDE) application to initiate a US trial of its Calibreye titratable ...

Q2-2025 Ophthalmic Revenue Roundup for Tarsus, Immunocore, Harrow, ANI, Sight Sciences, and Iridex
Q2-2025 Ophthalmic Revenue Roundup for Tarsus, Immunocore, Harrow, ANI, Sight Sciences, and Iridex

Tarsus Pharmaceuticals, of Irvine, California, reported Aug. 6 that its Q2-2025 Xdemvy net product revenue was $102.7 million, a 152 percent increase over $40.8 million in Q2-2024. The company said...

EMA Selects Annexon’s GA Candidate for Regulatory Pilot Program
EMA Selects Annexon’s GA Candidate for Regulatory Pilot Program

Annexon announced Aug. 7 that vonaprument (formerly ANX007), the company’s treatment candidate for geographic atrophy, was among the programs selected by the European Medicines Agency (EMA) to part...

Moran Celebrates Approval of AI Tech to Help Time Injections for Wet AMD
Moran Celebrates Approval of AI Tech to Help Time Injections for Wet AMD

The John A. Moran Eye Center is celebrating European regulatory approval of AI technology that assists ophthalmologists in timing intravitreal injections in wet age-related macular degeneration (AM...

First Commercial Procedure Performed with Encelto, Only FDA-Approved Treatment for MacTel
First Commercial Procedure Performed with Encelto, Only FDA-Approved Treatment for MacTel

Neurotech Pharmaceuticals, of Cumberland, Rhode Island, announced Aug. 11 the first commercial surgical procedure for Encelto, the only US FDA-approved treatment for macular telangiectasia (MacTel)...

First Commercial Procedure Performed with BVI’s Laser Endoscopy System for Glaucoma
First Commercial Procedure Performed with BVI’s Laser Endoscopy System for Glaucoma

BVI Medical announced July 31 the first clinical use of its Leos laser endoscopy system for glaucoma. BVI, of Waltham, Massachusetts, says Leos offers a more intuitive, minimally invasive ab intern...

US FDA Grants Fast Track Status to AAVantgarde’s Stargardt Candidate
US FDA Grants Fast Track Status to AAVantgarde’s Stargardt Candidate

Italy’s AAVantgarde Bio announced Aug. 12 that the US FDA had granted fast track status to AAVB-039, its gene therapy candidate for Stargardt disease. AAVB-039 aims to address the underlying geneti...

VSY Biotechnology Launches Enova Hydrophobic IOLs with Rotaryjet Inserter
VSY Biotechnology Launches Enova Hydrophobic IOLs with Rotaryjet Inserter

Germany’s VSY Biotechnology announced Aug. 8 that its Enova hydrophobic intraocular lens (IOL) line was now available with the company’s Rotaryjet preloaded delivery system. VSY said the Rotaryjet ...

Alcon Agrees to Acquire STAAR Surgical in Deal Worth $1.5 Billion
Alcon Agrees to Acquire STAAR Surgical in Deal Worth $1.5 Billion

—STAAR’s Evo ICL fills a strategic gap in Alcon’s surgical portfolio, broadening its refractive product line while bolstering STAAR’s global commercialization. The Deal: Alcon will acquire STAAR Su...

Q2-2025 Ophthalmic Revenue Roundup for Regeneron, Amgen, AbbVie, Hoya, and Ocular Therapeutix
Q2-2025 Ophthalmic Revenue Roundup for Regeneron, Amgen, AbbVie, Hoya, and Ocular Therapeutix

Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2025 US revenue for Eylea HD and Eylea 2 mg was $1.15 billion, a 25 percent decrease from $1.53 billion in Q2-2024. Eylea HD accounted...

​US CMS Issues J-Code for Encelto, Q-Code for Yesafili for Billing Payers
​US CMS Issues J-Code for Encelto, Q-Code for Yesafili for Billing Payers

The US Centers for Medicare and Medicaid Services (CMS) issued a J-code for Neurotech’s Encelto and a Q-code for Biocon Biologics’ Yesafili during Q2-2025. The codes take effect Oct. 1, 2025. In ad...

Eye Physicians, Researchers Band Together to Stave Off NEI Cuts, Consolidation
Eye Physicians, Researchers Band Together to Stave Off NEI Cuts, Consolidation

The American Academy of Ophthalmology (AAO) announced July 23 that it had joined with other professional and vision research organizations to fight proposed funding cuts and consolidation threats a...

Regenxbio Plans Pivotal Program for DR Gene Therapy, Amends Deal with AbbVie
Regenxbio Plans Pivotal Program for DR Gene Therapy, Amends Deal with AbbVie

Regenxbio announced Aug. 7 that it was planning a pivotal program for its suprachoroidal gene therapy candidate in diabetic retinopathy (DR)—along with a corresponding amendment to its collaboratio...

Topcon Healthcare Acquires Retinal Screening Platform to Improve Bidirectional Referrals
Topcon Healthcare Acquires Retinal Screening Platform to Improve Bidirectional Referrals

Topcon Healthcare reported July 31 that it had acquiredIntelligent Retinal Imaging Systems (IRIS), a Pensacola, Florida-based developer of cloud-based retinal screening technology. No financial det...

EMA Grants Orphan Designation to Aldeyra’s Methotrexate Injection for RP
EMA Grants Orphan Designation to Aldeyra’s Methotrexate Injection for RP

Aldeyra Therapeutics announced July 24 that the European Medicines Agency (EMA) had granted orphan designation for ADX-2191 (methotrexate intravitreal injection) for inherited retinal dystrophies o...

Aeye Health Appoints Pamela F. Gallin, MD, as Chief Medical Officer
Aeye Health Appoints Pamela F. Gallin, MD, as Chief Medical Officer

Aeye Health announced July 31 that it had appointed Pamela F. Gallin, MD, as its chief medical officer. Gallin is a clinical professor of ophthalmology in pediatrics at the Morgan Stanley Children’...

US FDA Approves Lenz’ Vizz (Aceclidine) Drops for Presbyopia
US FDA Approves Lenz’ Vizz (Aceclidine) Drops for Presbyopia

Lenz Therapeutics announced July 31 that the US FDA had approved Vizz (aceclidine ophthalmic solution) 1.44% for presbyopia. The company said Vizz was the first once-daily, preservative-free eye dr...

Q2-2025 Ophthalmic Revenue Roundup for Roche, Bausch + Lomb, Apellis, Glaukos, and Astellas
Q2-2025 Ophthalmic Revenue Roundup for Roche, Bausch + Lomb, Apellis, Glaukos, and Astellas

Swiss company Roche reported July 24 that Vabysmo sales for Q2-2025 were CHF 1.05 billion ($1.3 billion, converted June 30, 2025), a 19 percent increase over CHF 947 million in Q2-2024. Roche said ...

CMS Proposes Lower Physician Payments in 2026, Higher HOPD and ASC Fees
CMS Proposes Lower Physician Payments in 2026, Higher HOPD and ASC Fees

US ophthalmologists are gaining some clarity on what their reimbursement for treating Medicare patients may look like in 2026. Documents published by the Centers for Medicare and Medicaid Services ...

Boehringer Ingelheim and Re-Vana Sign Potential $1 Billion Collaboration Deal
Boehringer Ingelheim and Re-Vana Sign Potential $1 Billion Collaboration Deal

Boehringer Ingelheim and Re-Vana Therapeutics will collaborate to develop extended-release therapies for eye diseases in a deal worth potentially more than $1 billion for Re-Vana, the companies ann...

Alcon Launches Tryptyr (Acoltremon) Drops for Dry Eye in US
Alcon Launches Tryptyr (Acoltremon) Drops for Dry Eye in US

Alcon announced July 29 the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% to treat the signs and symptoms of dry eye. Tryptyr is a first-in-class TRPM8 agonist, dose...

New Minnesota Law Expands ODs’ Authority to Prescribe Drugs, Perform Injections
New Minnesota Law Expands ODs’ Authority to Prescribe Drugs, Perform Injections

A new law passed in Minnesota expands optometrists’ authority to prescribe certain medications and allows them to administer some in-office injections. The Minnesota Optometric Association (MOA) ha...

Innovia Medical Acquires Ophthalmic Surgical Instrument Maker Hurricane Medical
Innovia Medical Acquires Ophthalmic Surgical Instrument Maker Hurricane Medical

Innovia Medical, of St. Paul, Minnesota, reported July 2 that it had acquired Bradenton, Florida-based Hurricane Medical, manufacturer of ophthalmic surgical instruments, as well as Memphis, Tennes...

Glaukos Acquires Mobius Therapeutics and its Mitosol Antifibrotic Agent
Glaukos Acquires Mobius Therapeutics and its Mitosol Antifibrotic Agent

Glaukos announced during its earnings call on July 30 that it had acquired Mobius Therapeutics, of St. Louis, Missouri, whose lead compound, Mitosol, is the only FDA approved ophthalmic formulation...

Aflibercept Biosimilar Candidate from Alteogen Gains Positive CHMP Opinion
Aflibercept Biosimilar Candidate from Alteogen Gains Positive CHMP Opinion

South Korea’s Alteogen announced July 28 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended approval for Eyluxvi (ALT-L9), its proposed biosi...

UM Whole Eye Transplant Project Overcomes Two Hurdles
UM Whole Eye Transplant Project Overcomes Two Hurdles

Two critical pieces needed to eventually transplant a whole eye have been created and tested successfully at the University of Miami, the school reported July 24. Seventeen UM faculty members are w...

Exonate Plans Phase IIb Trial of Retinal Eye Drop Candidate in NPDR
Exonate Plans Phase IIb Trial of Retinal Eye Drop Candidate in NPDR

British company Exonate announced July 29 that it planned a Phase IIb clinical trial for lead compound EXN407, an eye drop candidate targeting retinal vascular diseases, in patients with non-prolif...

Unity Board Dissolves Company, Ending Research Targeting Senescent Cells
Unity Board Dissolves Company, Ending Research Targeting Senescent Cells

Unity Biotechnology’s board agreed on June 27 to dissolve the South San Francisco, California, company after evaluating strategic alternatives. The Nasdaq delisted Unity’s stock on July 9. Both mov...

Santen Launches Ryjunea Drops in Germany for Pediatric Myopia
Santen Launches Ryjunea Drops in Germany for Pediatric Myopia

Japan’s Santen Pharmaceutical announced July 22 that it had launched Ryjunea low-dose atropine eye drops in Germany for pediatric myopia. Germany is the first market for Ryjunea, which received EU ...

George Tidmarsh, MD, PhD, Named to Lead FDA’s Center for Drug Evaluation and Research
George Tidmarsh, MD, PhD, Named to Lead FDA’s Center for Drug Evaluation and Research

The US FDA reported July 21 that George Tidmarsh, MD, PhD, had been named director of the Center for Drug Evaluation and Research. Tidmarsh, a Stanford University faculty member and physician scien...

First Patient Treated in US Trial of Eyetronic Optic Nerve Therapy for Glaucoma
First Patient Treated in US Trial of Eyetronic Optic Nerve Therapy for Glaucoma

The Glaucoma Center of San Francisco announced July 21 that it had treated the first patient in the US as part of a clinical trial of Eyetronic, a non-invasive therapy to stimulate the optic nerve....

Octane Examines Changing Refractive Surgery Landscape
Octane Examines Changing Refractive Surgery Landscape

The 2025 Octane Ophthalmology Tech Forum examined why lens-based procedures are gaining momentum at the expense of traditional refractive surgery. It also looked at the pivotal role that artificial...

Viatris’ Phase III Blepharitis Ointment Candidate Fails to Reach Primary Endpoint
Viatris’ Phase III Blepharitis Ointment Candidate Fails to Reach Primary Endpoint

Viatris announced July 18 that a Phase III trial of pimecrolimus 0.3% (MR-139) ophthalmic ointment in blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks ...

Bioeq Licenses Lucentis Biosimilar to Bio Usawa for Sub-Saharan Africa
Bioeq Licenses Lucentis Biosimilar to Bio Usawa for Sub-Saharan Africa

Swiss company Bioeq announced July 1 that it had licensed its Lucentis (ranibizumab) biosimilar to African biotech company Bio Usawa for marketing in sub-Saharan Africa under the brand name BioUcen...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more